相关实验视频
Updated: Sep 8, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
更高的教育程度和加速的积在阿尔茨海默氏症疾病中
Yue Cai1, Lili Fang1, Jie Yang1,2
1Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
JAMA neurology
|July 7, 2025
概括
更高的教育程度 (EA) 加快了粉样β斑块 (Aβ+) 的个体的积. 然而,Aβ向治疗可能会减缓Aβ+个体具有较高EA的tau进展,这表明Aβ清除的作用.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 纵向的积是阿尔茨海默病 (AD) 的一个关键特征.
- 教育程度 (EA) 对病态进展的影响还不清楚.
研究的目的:
- 调查教育成就 (EA) 与阿尔茨海默氏症 (AD) 中的陶积累之间的关联.
- 探索EA如何与粉样β (Aβ) 负担和其他生物标志物相互作用以影响病理.
- 评估Aβ向治疗对与EA相关的tau积累的影响.
主要方法:
- 一项使用三个独立数据集的队列研究:ADNI,A4和GHABS.
- 分析包括接受了粉样βPET扫描和tau PET扫描的参与者.
- 测量包括化 (p-tau) 217和休息状态功能性MRI (RS-fMRI).
主要成果:
- 在β-粉样蛋白阴性个体中,较高的EA与较慢的tau积累相关.
- 相反,在粉样β阳性 (Aβ+) 个体中,较高的EA与加速的tau积累和传播有关.
- 在Aβ+个体中,较高的EA与Aβ负担,内分泌和血p-tau217.2具有更强的关联.
- 针对Aβ的治疗似乎可以减轻Aβ+个体具有更高EA的血p-tau217相关的tau积累.
结论:
- 更高的教育程度与的加速积累和扩散有关,而粉样质斑块的个体.
- 这些发现强调了粉样β清除在调节的进展中的关键作用,特别是在EA较高的个体中.
- 针对粉样蛋白的干预措施可能对于在特定患者亚组中管理tau病理至关重要.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260

